Radiopharmaceutical developer Draxis Health said that its DraxImage medical imaging subsidiary has received FDA approval to manufacture the company’s lyophilized products at an in-house facility in Kirkland, Quebec. The move will enable DraxImage to replace an outside manufacturer, thus saving $700,000 (U.S.) a year in outsourcing costs.
The DraxImage products are labeled at the site of use with technetium, and are used in kidney, lung, bone, and brain scans. Shipments of DTPA, the first of the products covered by the FDA approval, began in January.
By AuntMinnie.com staff writersMarch 14, 2002
Related Reading
Draxis gets NRC approval for BrachySeed Pd-103, November 13, 2001
Draxis revenues climb, November 8, 2001
DraxImage to make radiotherapy capsules for Bracco, August 23, 2001
Draxis posts higher revenues in Q2, August 13, 2001
DraxImage gets clearance for palladium version of BrachySeed, June 28, 2001
Copyright © 2002 AuntMinnie.com
